TY - JOUR
T1 - Complete response of hepatocellular carcinoma with systemic combination chemotherapy
T2 - Not to get out the chemotherapy?
AU - Boschetti, Gilles
AU - Walter, Thomas
AU - Hervieu, Valérie
AU - Cassier, Philippe
AU - Lombard-Bohas, Catherine
AU - Adham, Mustapha
AU - Scoazec, Jean Yves
AU - Dumortier, Jérôme
PY - 2010/1/1
Y1 - 2010/1/1
N2 - Since 2007, sorafenib is the new standard for the first-line treatment of advanced hepatocellular carcinoma (HCC), with proved effectiveness on survival, but no complete response. We encountered a case of complete and durable response after gemcitabine plus oxaliplatine (GEMOX) in a patient with metastatic HCC. The use of GEMOX was considered because the patient was young, without other liver disease, with bone and hepatic lesions, a rapidly progressive disease, and a poorly differentiated component on histological aspect. After 12 cycles of GEMOX, complete response occurs with disappearance of metastases and normalization of serum level of α-fetoprotein. This is the first case report of complete response of HCC to GEMOX. That is why the association of chemotherapy and molecular targeted therapies is a promising direction of research. Our report shows that another important challenge remains in the identification of predictive factors of response to standard chemotherapy or molecular targeted agents.
AB - Since 2007, sorafenib is the new standard for the first-line treatment of advanced hepatocellular carcinoma (HCC), with proved effectiveness on survival, but no complete response. We encountered a case of complete and durable response after gemcitabine plus oxaliplatine (GEMOX) in a patient with metastatic HCC. The use of GEMOX was considered because the patient was young, without other liver disease, with bone and hepatic lesions, a rapidly progressive disease, and a poorly differentiated component on histological aspect. After 12 cycles of GEMOX, complete response occurs with disappearance of metastases and normalization of serum level of α-fetoprotein. This is the first case report of complete response of HCC to GEMOX. That is why the association of chemotherapy and molecular targeted therapies is a promising direction of research. Our report shows that another important challenge remains in the identification of predictive factors of response to standard chemotherapy or molecular targeted agents.
KW - chemotherapy
KW - complete response
KW - hepatocellular carcinoma
UR - http://www.scopus.com/inward/record.url?scp=77955217888&partnerID=8YFLogxK
U2 - 10.1097/MEG.0b013e328336565a
DO - 10.1097/MEG.0b013e328336565a
M3 - Article
C2 - 20075738
AN - SCOPUS:77955217888
SN - 0954-691X
VL - 22
SP - 1015
EP - 1018
JO - European Journal of Gastroenterology and Hepatology
JF - European Journal of Gastroenterology and Hepatology
IS - 8
ER -